Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TYMP | P19971 | 3/20 | 0.49 |
| ▸ | TK1 | P04183 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17013819 | 0.86 | MAPK1 (0.56) | MAPK1HPGDTYMPTK1 | |
| SCHEMBL456749 | 0.84 | HPGD (0.57) | MAPK1HPGDTYMPTK1 | |
| SCHEMBL11983370 | 0.84 | MAPK1 (0.54) | MAPK1HPGDTYMPTK1 | |
| SCHEMBL13724897 | 0.83 | TYMP (0.54) | MAPK1HPGDTYMPTK1 | |
| SCHEMBL28985696 | 0.83 | TK1 (0.37) | MAPK1HPGDTYMPTK1 | |
| SCHEMBL5353008 | 0.83 | HPGD (0.55) | MAPK1HPGDTYMPTK1 | |
| SCHEMBL8014516 | 0.82 | KMT2A (0.40) | MAPK1 | |
| SCHEMBL7643586 | 0.81 | MAPK1 (0.51) | MAPK1HPGDTYMPTK1 | |
| SCHEMBL28113909 | 0.81 | KMT2A (0.40) | — | |
| SCHEMBL17013820 | 0.81 | MAPK1 (0.54) | MAPK1HPGDTYMPTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115960480-B | Light response self-repairing material containing thymine derivative and application thereof | 合肥工业大学 | 2023-09-12 | — | — | CN | claimed |
| CN-115960480-A | Light response self-repairing material containing thymine derivative and application thereof | 合肥工业大学 | 2023-04-14 | — | — | CN | claimed |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | EyePoint Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4414032-A2 | METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 | EyePoint Pharmaceuticals, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3977994-B1 | ACTIVATORS OF TIE-2 FOR USE IN TREATING INTRAOCULAR PRESSURE | EYEPOINT PHARMACEUTICALS INC (US) | 2024-04-24 | — | — | EP | disclosed |
| CN-116143707-B | Base ionizable lipid and preparation method and application thereof | 山东大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-115960480-B | Light response self-repairing material containing thymine derivative and application thereof | 合肥工业大学 | 2023-09-12 | — | — | CN | disclosed |
| CN-116143707-A | Base ionizable lipid and preparation method and application thereof | 山东大学 | 2023-05-23 | — | — | CN | disclosed |
| US-11633718-B2 | Removal of bacteria from drinking water via filtration | INSTRACTION GMBH (DE) | 2023-04-25 | — | — | US | disclosed |
| CN-115960480-A | Light response self-repairing material containing thymine derivative and application thereof | 合肥工业大学 | 2023-04-14 | — | — | CN | disclosed |
| US-20220274976-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint, Inc. | 2022-09-01 | — | — | US | disclosed |
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-03-15 | — | — | US | disclosed |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHONOLOGICAL UNIVERSITY (SG) | 2011-10-06 | — | — | US | disclosed |
| WO-2010027326-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-03-11 | — | — | WO | disclosed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| US-6414013-B1 | KINASE INHIBITORS; ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | MAPK1 3990/4885HPGD 4559/4885TYMP 4809/4885 |
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | MAPK1 3389/4885HPGD 2504/4885TYMP 3584/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | MAPK1 3389/4885HPGD 2504/4885TYMP 3584/4885 |
| US-20220274976-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | MAPK1 3966/4885HPGD 584/4885TYMP 51/4885 |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | TIE1, TEK, KDR | MAPK1 3966/4885HPGD 584/4885TYMP 51/4885 |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | MAPK1 3990/4885HPGD 4559/4885TYMP 4809/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | MAPK1 2492/4885HPGD 2843/4885TYMP 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.